Queensland Bauxite Limited

World’s First venture: Queensland Bauxite Ltd (ASX: QBL) has announced that VitaCann Pty Ltd has signed an exclusive joint venture agreement for a World First Pharmaceutical Grade Medical Cannabis Extended Release Pill with Canntab Therapeutics Limited of Toronto, Ontario, Canada. VitaCann is a wholly owned subsidiary of Medical Cannabis Limited (MCL), which is a subsidiary of QBL. QBL is excited to bring in Australia the new product in the world cannabis market, that will be accepted by the medical industry at large due to the unique benefits and advantages. Moreover, MCL considers the product to be a game changing medicinal solution. New Australian Federal Government export has given approval to MCL to expand production, processing and manufacture of the product. Further, the Australian Government has put in place the legislation to enable a consistent pharmaceutical grade GMP quality pill product such as the Canntab pill now secured by VitaCann, to be approved as a general prescription medication subject to an established approval process.
 

Effect of Canntab Extended Release Tablets (Source: Company Reports)
 
With this news, QBE stock that fell 44.68% in last one month as on January 8, 2018 owing to volatility, recovered by about 44.2% on January 09, 2018 post reinstatement to official quotation. While the above move is a major milestone, the stock will be an interesting one to watch for any potential buying opportunity with more catalysts, if any, that the group may reveal going forward. As of now, QBL looks “Expensive” at the current price of $0.075

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.